1. Immunohistochemical Detection of 5T4 in Renal Cell Carcinoma
   Christopher P. Miller et al, 2023, Applied Immunohistochemistry & Molecular Morphology CrossRef
2. Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
   Yuexin Xu et al, 2021, Human Vaccines & Immunotherapeutics CrossRef
3. Autoantibody against arrestin-1 as a potential biomarker of renal cell carcinoma
   Alexey V. Baldin et al, 2019, Biochimie CrossRef
4. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
   David A. Braun et al, 2021, Nature Reviews Clinical Oncology CrossRef
5. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients
   Takeshi Ishikawa et al, 2021, Cancer Immunology, Immunotherapy CrossRef
6. Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma
   Hirokazu Matsushita et al, 2016, Cancer Immunology Research CrossRef
7. MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
   Mikiya Ishihara et al, 2020, BMC Cancer CrossRef
8. NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma
   Shugo Ueda et al, 2018, Oncotarget CrossRef
9. Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
   Shinichi Kageyama et al, 2015, Clinical Cancer Research CrossRef